Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say
Executive Summary
The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles